None listed
Conditions
Interventions
Intervention1: Nutraceutical-1,2,3: 2 tablets twice daily to be consumed orally for 30 days: Botanical formulation of extracts from Cinnamon, Moringa, Bitter Melon, Fenugreek, Gymnema and Ginger
Contr
Sponsors
Amway India Enterprises Pvt Ltd
Siro Clinpharm Pvt Ltd
Eligibility
Inclusion criteria
Inclusion criteria: 1. Male or female aged between 25-65 years 2. Subjects with BMI of >=23 to 3. Subject with a HbA1c levels of 5.7-6.4% (39-46 mmol/mol) as per the American Diabetes Association at the time of screening 4. Subjects with liver (alanine transaminase, aspartate transaminase, total and direct bilirubin, gamma glutamyl transferase, alkaline phosphatase, total proteins, and albumin) and renal (serum creatinine and blood urea nitrogen) function parameters within normal laboratory reference range at screening 5. Females of childbearing potential must have a negative serum pregnancy test (human chorionic gonadotropin, beta subunit [β-hCG]) at screening 6. Males and females of childbearing potential willing to practice appropriate birth control during the entire duration of the study. Appropriate birth control is defined in the study as any medically recommended method (or combination of methods) except oral birth control pills as per standard of care 7. Subject is willing to provide written informed consent 8. Subject is willing, able and likely to comply with all study procedures and restrictions
Exclusion criteria
Exclusion criteria: 1. Subject with a history of diabetes mellitus (type 1/ type 2/ gestational/secondary etc.) 2. Subject has used any anti-diabetic medication for blood sugar control or other medical conditions (e.g. metformin in polycystic ovarian disease)any time during the past 6 months 3. Subject is taking medications known to interfere with glucose metabolism e.g. systemic corticosteroids, protease inhibitors, antidepressants, or antipsychotics) or any other medications in the opinion of investigator that may interfere with study outcomes 4. Subjects with a history of use of other herbal or nutritional supplements that modify glucose absorption and/or metabolism in the past 6 months 5. Subjects with a history of use of weight loss drugs (orlistat, lorcaserin, phentermine-topiramate, naltrexone-bupropion etc) in the past 6 months. 6. Subject has had a weight loss or gain of greater >=5% of body weight in the 6 months prior to screening. 7. Hemoglobin levels of 8. Subject with a history of clotting/bleeding disorders such as hemophilia,Von Willebrand disease, disseminated intravascular coagulation, vitamin K deficiency or subjects who required blood transfusion in the past 3 months. 9. Subject with history of significant renal, hepatic, cardiovascular, hematologic, metabolic, ophthalmologic, respiratory, gastrointestinal, cerebrovascular, neurologic, endocrine dysfunction, malignancy, or any other significant medical illness or disorder which, in the judgment of the investigator could interfere with the study or require treatment(s) which might interfere with study or which may pose risk to the patient 10. History of drug abuse or alcohol consumption ( >20 g/day in women and >30 g/day in men) and smoking ( >5 pack-years cigarettes) 11. History of participation in other interventional studies within last 60 days 12. History of blood donation within last 30 days 13. Subjects with inadequate peripheral venous access, such that intravenous catheterization for serial blood collection is difficult. 14. Subject is pregnant or breast-feeding at the time of screening, or planning to be pregnant during the study 15. Subject has known allergies to the herbal products or allergy to any of the components of the study product 16. Any other condition, that in the investigatorâ??s judgment, might interfere with study objectives
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Safety : number of subjects reporting any AE, treatment emergent AE (TEAE), any serious AE (SAE), any study product-related AE, any study product related SAE, and discontinuations due to AE. Efficacy endpoints: change in blood glucose levels based on OGTT after 30 days of treatment with study products change in fructosamine, fasting plasma glucose level and serum Insulin levels, fasting serum lipids and body weight from Baseline to 30 days between the treatment armsTimepoint: 30 days of study product administration | — |
Secondary
| Measure | Time frame |
|---|---|
| NATimepoint: NA | — |
Countries
India
Contacts
Public ContactMr Partha Chatterjee
SIRO Clinpharm pvt ltd
Outcome results
None listed